# Holdings deep dive — 2026-09-06

Five-agent run: `holdings`, `filings`, `calendar`, `news`, `red-team`.
Scope and caps per `reports/00-run-brief.md`.

**Market state:** closed. Friday 2026-09-04 was the last session; Monday
2026-09-07 is Labor Day. Every price in this report is a Friday close or
after-hours print, not a live quote. That is a limitation of when the run
happened, not of the tools.

**No recommendations appear anywhere in this document.** No agent was
permitted to produce one, `red-team` included.

---

# 1. OPEN QUESTIONS

What the team could not resolve. Placed first by explicit instruction — this
is the part worth reading.

## 1.1 Job #2 did not run. `get_sec_filing` is down.

The MD&A / risk-factor diff — the entire second job this system was built
for — **produced nothing**, for any ticker.

`get_sec_filing` returned `API error 404: "Filing content is not available"`
on **8 of 8 attempts**, spanning all five tickers and four form types
(10-Q, 10-K, 8-K, 6-K). `filings` retested against unrelated filings to rule
out a bad filing_id and got identical failures. This is a systemic outage of
the section-reading endpoint, not a per-company problem.

**This must not be read as "nothing changed."** No comparison was possible.
The MD&A and risk-factor question for CRDO, INTC, and IREN is **unresolved**,
not benign. `red-team` independently confirmed the distinction is
load-bearing and easy to lose in summary.

Filing pairs were correctly identified and are ready for a retry:

| Ticker | Most recent | Prior comparable |
|---|---|---|
| CRDO | 10-Q filed 2026-09-02 (Q1 FY2027, period 2026-08-01) | 10-Q filed 2025-09-04 (period 2025-08-02) |
| INTC | 10-Q filed 2026-07-23 (Q2 FY2026, period 2026-06-27) | 10-Q filed 2025-07-24 |
| IREN | 10-K filed 2026-08-27 (FY2026) | 10-K filed 2025-08-28 |

## 1.2 SPCX cannot be explained by anything this team can reach

Three agents produced three partial pictures that do not reconcile:

- `filings`: **zero SEC filings of any type.**
- `calendar`: **real quarterly earnings history** — 2026-08-04 reported,
  verified, actual −$0.09 vs estimate −$0.16; next 2026-11-17.
- `news`: press coverage treating SpaceX as an operating aerospace company.
- `red-team` (fresh pull, 2026-09-06): market cap **$2.008 trillion**,
  13.57B shares outstanding, real daily OHLCV (open $148.66, volume 49.1M on
  2026-09-04), 52-week range $104.83–$225.64.

The user holds **1 live call contract** on it (exp. 2026-09-18, avg cost
$127.00/contract, marked $117.00). So: an actively traded, fully marked,
currently held position in an instrument that structurally cannot produce a
10-Q. Whether it is an ADR, a synthetic wrapper, a private-market proxy, or
something else is **not determinable from any tool available to this team.**

## 1.3 Same-day realized P&L is provisional

Two pulls of the *same closed day* produced different numbers:

| When pulled | 2026-09-04 realized P&L | Trades |
|---|---|---|
| Friday evening, 2026-09-05 ~01:43 UTC | −$321.94 | 15 |
| This run, 2026-09-06 | **−$484.94** | **18** |

`red-team` re-pulled independently and got −$484.94 / 18, confirming the
current figure and that the number genuinely **moved after the fact** rather
than one pull being a copy error. Three additional closing trades and about
−$163 appeared after the first snapshot, consistent with the JPM/FCX/SPCX
09-04 contracts settling.

**Unresolved:** how long the settling delay runs. If a later pull produces a
third number, same-day P&L cannot be treated as final at all.

## 1.4 A ticker was misidentified, and the error propagated

`holdings` labeled MMED as **"MindMed"** in its position list — an inference
from the ticker, never verified. The orchestrator then copied that label into
the prompts sent to `filings`, `calendar`, and `news`.

`news` caught it and refused to accept the label:

> **MMED is MiniMed Group, Inc.** — a diabetes-device company (insulin
> pumps, CGM), Nasdaq IPO March 2026, majority-owned by Medtronic.
> MindMed trades as **MNMD**.

`filings` independently corroborated via `get_equity_fundamentals`: MiniMed
Group Inc, Northridge CA, founded 1983, CEO Que Thanh Dallara, ~8,000
employees, market cap ~$6.56B (2026-09-04). Zero SEC filings on record.

The position is 2 shares. The error was caught before reaching this report,
but only because one agent checked its input rather than trusting it.

## 1.5 PBR has no annual report in this filing index

No 20-F back to 2024-01-01 — only 6-K current reports, which also 404'd.
`get_financials` returned **null** for PBR entirely. As a foreign private
issuer its MD&A and risk factors live in a 20-F, so there is nothing to diff
even once the outage clears. Reported financials for PBR are unavailable
through these tools.

## 1.6 Data-quality flags carried forward unresolved

- **MMED**: two past-dated quarters (2026-05-10, 2026-08-10) still show
  `actual: null`. May be fiscal-vs-calendar labeling; not confirmable.
- **PBR**: next earnings 2026-11-10 is `verified: true` but the `timing`
  field returned **null** — reported as-is rather than guessed.
- **INTC / IREN**: both upcoming dates are `verified: false` — scheduled but
  unconfirmed.
- **A bug in this system's own hook**: `mcp__Me__search` is read-only but
  does not match `^mcp__Me__get_`, so the default-deny PreToolUse hook blocks
  it despite it being in three agents' allowlists. `filings` hit this. The
  same false positive would hit `run_scan`. Fix pending.

---

# 2. WHAT EACH AGENT FOUND

## 2.1 `holdings` — position report

*79k tokens, 28 tool calls. All quotes 2026-09-04.*

**Four accounts, none unclassifiable:**

| Account | Classification | Total value | Cash |
|---|---|---|---|
| ••••1403 | Taxable, self-directed | $965.41 | $309.87 |
| ••••3408 "Agentic" | Taxable, agentic | $97.50 | $11.48 |
| ••••2582 | Roth IRA | $0.00 | $0.00 |
| ••••0155 "Smart Income" | Managed | $100.09 | $100.09 |

Labeled sum of total values: **$1,163.00**. Realized P&L is *not* summed
across accounts, by rule.

**Equity positions**

| Acct | Symbol | Qty | Avg cost | Current | As of | Unrealized |
|---|---|---|---|---|---|---|
| 1403 | CRDO | 1 | $170.72 | $169.5372 | 09-04 23:59:43Z (AH) | −$1.18 |
| 3408 | PBR | 2 | $20.94 | $20.18 | 09-04 23:10:39Z (AH) | −$1.52 |
| 3408 | MMED | 2 | $23.32 | $22.83 | 09-04 21:41:15Z (AH) | −$0.98 |

All three show `shares_held_for_sells` equal to full quantity and
`shares_available_for_sells` = 0 — held against pending sell orders
(protective stops).

**Option positions** — all in ••••1403, all quotes `updated_at`
2026-09-04T19:59:59Z, values from `adjusted_mark_price`:

| Underlying | Exp | Qty | Avg cost/ct | Mark | Value | Unrealized |
|---|---|---|---|---|---|---|
| IREN | 09-18 | 1 | $118.00 | $1.40 | $140.00 | **+$22.00** |
| INTC | 09-11 | 1 | $134.00 | $1.33 | $133.00 | −$1.00 |
| SPCX | 09-18 | 1 | $127.00 | $1.17 | $117.00 | −$10.00 |
| METU | 09-18 | 2 | $48.00 ea | $0.48 | $96.00 | $0.00 |

Sum = **$486.00**, reconciling exactly to the account's reported
`options_value`. That exact reconciliation is meaningful evidence the option
pricing path is wired correctly.

**Expirations — confirmed settled.** JPM, FCX, and SPCX contracts expiring
2026-09-04 are all at quantity 0. `holdings` went looking for them by
expiration-date filter rather than merely noting their absence, and found
something the run brief had wrong: there were **two** separate SPCX 09-04
lots (avg $46.00 and $77.00), not one.

**Realized P&L — taxable only, Roth withheld by rule.** ••••1403, 3-month
window: **−$353.68 (−6.46%)**.

| Date | Realized | Trades |
|---|---|---|
| 08-26 | −$4.00 | 1 |
| 08-28 | −$475.40 | 10 |
| 08-31 | −$2.34 | 5 |
| 09-01 | +$42.00 | 11 |
| 09-02 | +$173.00 | 3 |
| 09-03 | +$398.00 | 15 |
| 09-04 | **−$484.94** | 18 |

••••3408: $0.00. ••••0155 (managed): −$0.17, 5 trades. Roth: withheld.

Tax lots not pulled — per-symbol and out of scope for a broad report.
Available on request for CRDO, PBR, MMED.

## 2.2 `filings` — blocked, plus two classifications

*75k tokens, 32 tool calls.*

Primary task blocked (see §1.1). Two secondary findings, both solid:

**METU — confirmed 2x leveraged META ETP, not an operating company.**
Filing index shows only N-CSRS, 497K, and 497 forms — registered
investment-company filings, exclusive to funds under the '40 Act. No 10-K or
10-Q exists. `get_equity_fundamentals` description: *"METU provides 2x
leveraged exposure, less fees and expenses, to the daily price movement for
shares of META stock."* Industry: "Investment Trusts Or Mutual Funds."

**MMED — MiniMed Group** (see §1.4). Zero SEC filings.

**`get_financials` worked** where `get_sec_filing` did not. Quarterly, pulled
this run:

| CRDO | Revenue | Net income | Net margin |
|---|---|---|---|
| Q1 FY2027 (2026-08-01) | $479.0M | $129.4M | 27.0% |
| Q4 FY2026 (2026-05-02) | $437.0M | — | 38.7% |
| Q3 FY2026 (2026-01-31) | $407.0M | — | 38.6% |
| Q2 FY2026 (2025-11-01) | $268.0M | — | 30.8% |

Revenue rising every quarter; net margin down from 38.7% to 27.0% in the
most recent one.

| INTC | Revenue | Net income | Net margin |
|---|---|---|---|
| Q2 FY2026 (2026-06-27) | $16.13B | **−$11.03B** | −68.4% |
| Q1 FY2026 (2026-03-28) | $13.58B | −$3.73B | −27.5% |
| Q4 FY2025 (2025-12-27) | $13.67B | −$0.59B | −4.3% |
| Q3 FY2025 (2025-09-27) | $13.65B | +$4.06B | +29.8% |

Four quarters from +$4.06B to −$11.03B. **No MD&A available to explain what
the filing attributes it to** — impairments, restructuring, or otherwise.

| IREN | Revenue | Net income | Net margin |
|---|---|---|---|
| Q4 FY2026 (2026-06-30) | $137.2M | **−$684.0M** | −498.5% |
| Q3 FY2026 (2026-03-31) | $144.8M | −$247.8M | — |
| Q2 FY2026 (2025-12-31) | $184.7M | −$155.4M | — |
| Q1 FY2026 (2025-09-30) | $240.3M | **+$384.6M** | +160.1% |

Revenue declining across the fiscal year while losses deepen sharply.

## 2.3 `calendar` — earnings dates

*19k tokens, 7 tool calls. Window 2026-09-06 → 2026-11-05.*

**Only two of the five report inside 60 days:**

| Symbol | In window | Date | Timing | Verified |
|---|---|---|---|---|
| INTC | **Yes** | 2026-10-22 | pm | **false** |
| IREN | **Yes** (day 60 exactly) | 2026-11-05 | pm | **false** |
| CRDO | No — next 2026-11-30 | pm | false |
| MMED | No — next 2026-11-10 | pm | false |
| PBR | No — next 2026-11-10 | **null** | true |

Neither in-window date is verified. Recent surprise history: CRDO has beaten
three straight (est $0.84/act $1.07; $0.98/$1.16; $1.12/$1.20). INTC has
beaten three straight ($0.04/$0.15; −$0.01/$0.29; $0.19/$0.42). IREN has
**missed** three straight (−$0.18/−$0.52; −$0.24/−$0.327; −$0.55/−$0.74).

Classification signals: METU returned an **empty earnings array** (consistent
with an ETP). SPCX returned **real earnings history** (inconsistent with an
ETP — see §1.2).

## 2.4 `news` — last 30 days, sourced

*84k tokens, 11 tool calls. All figures below are the cited outlet's claims,
not tool-verified.*

**CRDO** — FQ1 FY2027: revenue ~$479M vs $471.77M estimate; adjusted EPS
$1.20 vs $1.17 estimate (Benzinga, 2026-09-03; note the estimate conflict in
§3). GAAP gross margin **64.5%, down from 68.2%**; opex **$188.4M from
$89.6M**. Q2 guidance $525–535M revenue. CFO Dan Fleming forecast FY2027
revenue growth "more than 85%." Despite the beat, CRDO was **the Russell
1000's worst performer on 2026-09-02, −18.7~19%** to $165–169, which
Benzinga attributed to margin and cost focus rather than the headline.
Targets: JPMorgan Overweight $310; Evercore Outperform $292; Rosenblatt
Neutral $235; BofA Buy, cut $340→$275. Down ~27% over five sessions as of
2026-09-05.

**INTC** — Mizuho cut PT $109→$92, Neutral (MT Newswires, 2026-09-04);
FactSet consensus "overweight," mean PT $120.83. Fell ~3% premarket to
$86.88 on 09-01. **SK Hynix explicitly denied** a Herald Economy report that
it was considering Intel Foundry for HBM4E base-die production, telling MT
Newswires it is "not currently considering" it (2026-08-31). Rose ~4.1% on
09-04 in a semiconductor rally following a stronger-than-expected August
jobs report.

**IREN** — FQ4 2026 adjusted EBITDA ~$19M vs BTIG's ~$35M estimate; revenue
~$137M vs ~$132M estimate but **down from ~$187.3M a year earlier**. New
AI-cloud contract with an undisclosed "frontier AI lab," adding to ~$2.8B in
prior AI contracts; target ~$4B 2026 ARR against ~$1B currently. BTIG
reiterated Buy/$80. **Shares fell ~13.7~14% on 2026-08-28.** Blue Owl led a
**$2.4B debt financing at fixed 9.0%** for the Mackenzie Compute unit, PIMCO
participating. Sam Altman flagged "first signs" of "unsustainable silliness"
among neoclouds, with Benzinga naming IREN alongside Hut 8, Bitdeer and
Cipher (2026-09-02). Cramer, 2026-09-04, asked about IREN: *"the only one I
like is CoreWeave."*

**MMED / MiniMed** — Q1 sales $843M vs $827.065M estimate, **+16.6% YoY**
from $723M. US launch of "MiniMed Flex." Shares +7.1~7.5% to ~$24. Target
raises: BofA $24→$28, Mizuho $21→$26, UBS $25→$28, Deutsche Bank $20→$25.
UBS reported "no meaningful attrition" among Type 2 patients and that ~40% of
new US pump starts are Type 2. FactSet mean PT $25.55.

**PBR** — +4.96% to $20.31 on 2026-09-01 as energy rallied on **US strikes
on IRGC targets** following reported tanker attacks near the Strait of
Hormuz; WTI +4.7% to $90.46, Brent +4.6% to $95.05 the same day. Bloomberg
reported PBR weighing **LNG exports to Asia** after Qatari supply losses.
Bloomberg (2026-08-18): PBR weighing improved payment terms for **Braskem**
ahead of an 08-24 bankruptcy deadline, resisting an equity injection over
consolidation concerns. Confirmed direct negotiations for four offshore
blocks in **Ghana's Keta Basin**.

---

# 3. THE RED-TEAM CASE

*37k tokens, 7 tool calls. Read everything first, then verified five specific
claims. Gets the last word by design.*

## Assumptions the other four smuggled in

1. **Every "current" price is a frozen Friday snapshot.** All option marks
   (09-04 19:59:59Z) and equity prints (09-04 after-hours) predate this run.
   The picture is "as of Friday's close," and `holdings` never says so.
2. **Percentage moves are being read against a demonstration-scale account.**
   CRDO's −18.7% session costs the user **−$1.18 total**, because the
   position is one share. Treating these percentage swings as meaningful
   portfolio signal ignores that.
3. **News figures carry different epistemic weight than tool figures**, and
   the framing sometimes treats them as comparable.
4. **"No MD&A diff" and "no material change" are different things** — a
   distinction easily lost by the time it reaches a reader.

## What was checked, and what came back

**CRDO estimate conflict — resolved.** Fresh `get_earnings_results`
(2026-09-06): FQ1 FY2027 estimate **$1.12**, actual **$1.20**, verified
true. Matches `calendar`. Benzinga's $1.17 does not reconcile with any tool
here. *The actual print is not in dispute; which estimate you anchor to is.
Against $1.12 the beat is ~7%; against $1.17, ~3%.*

**SPCX — checked, unresolved.** See §1.2.

**P&L revision — confirmed real.** Fresh pull returns −$484.94 / 18 trades,
matching `holdings`, not the earlier −$321.94 / 15.

**METU's $0.00 — confirmed arithmetically correct, not a bug.** Fresh
`get_option_quotes`: adjusted mark **$0.48** against $48.00/contract cost, at
the identical snapshot. Theta −0.041/day, 12 days to expiration, on an
underlying that resets 2x daily.

## Breaking conditions

- **The estimate discrepancy breaks the precision of the "CRDO beat"
  framing, not its direction.** If a later report cites Benzinga's $1.17 as
  though it came from a tool, that is a sourcing error to catch on sight.
- **The SPCX position rests on an ownership question no tool here can
  close.** Any claim that "SpaceX's fundamentals" back that $117 option is
  unverifiable by any source this team has — not merely unverified today.
- **Same-day realized P&L is provisional.** If a third pull for 09-04
  produces a third number, same-day figures do not settle until some trailing
  delay, and any "how did today go" narrative built on one is subject to
  rewrite.
- **The IREN and INTC loss omissions change what "beat" means, not whether it
  happened.** IREN's ~$137M revenue beat sits beside a **−$684.0M net loss**
  the same quarter; INTC's price-target coverage sits beside a **−$11.03B**
  quarter. Neither loss appears in the news coverage. A reader taking "beat
  the estimate" as the whole picture is missing a number two orders of
  magnitude larger than the beat.
- **The MMED name error is a standing risk, not a one-time typo.** Holdings'
  position list still says "MindMed." Any future report reusing that label
  without cross-checking will describe the wrong company's risk profile
  against a real position.

## What survived the check

- Account totals, per-position dollar figures, and options valuations all
  reconcile against fresh pulls. Nothing fabricated, nothing stale beyond the
  expected weekend gap.
- CRDO's actual EPS ($1.20) and the `get_financials` figures for INTC and
  IREN are undisputed across all agents.
- The filings outage is a genuine tool failure (8/8 404s across five
  unrelated tickers and four form types), **not** a placeholder for "nothing
  changed."

---

## Run cost

| Agent | Tokens | Tool calls |
|---|---|---|
| holdings | 79,084 | 28 |
| filings | 74,696 | 32 |
| news | 83,897 | 11 |
| calendar | 19,299 | 7 |
| red-team | 37,328 | 7 |
| **Total (agents)** | **294,304** | **85** |

Against a 300–550k estimate with a target near the low end. The caps
(MD&A + risk factors only; ~3 articles per name) held — though the filings
cap was moot given the outage.
